Movement Alert｜Tempus AI Falls 5.47% in Regular Trading, Major Shareholder Continued Selling Pressures Market Sentiment

Market Focus00:03

On June 10, Tempus AI fell 5.47% in regular trading, trading at $45.965/share, with trading volume of $147 million. The decline comes amid persistent selling by major shareholder LEFKOFSKY ERIC P, whose concentrated share disposals have weighed heavily on market sentiment.

Notably, the Life Sciences Tools & Services sector posted broad gains on the day, with Thermo Fisher Scientific up 2.71%, Waters up 2.38%, and Agilent up 2.09%, highlighting that Tempus AI's weakness is stock-specific rather than sector-driven. The divergence underscores the outsized selling pressure at the individual stock level.

The stock had previously rallied significantly following FDA approval of its xT CDx next-generation sequencing platform, which made the company the first laboratory to hold FDA companion diagnostic approvals for both tumor-only and tumor-normal genomic profiling. The current decline is viewed as an extension of profit-taking combined with sustained institutional selling pressure following that run-up.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

1

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1125284512?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-10 00:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1125284512","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Tempus AI Falls 5.47% in Regular Trading, Major Shareholder Continued Selling Pressures Market Sentiment","media":"Market Focus","content":"<p><p>On June 10, Tempus AI fell 5.47% in regular trading, trading at $45.965/share, with trading volume of $147 million. The decline comes amid persistent selling by major shareholder LEFKOFSKY ERIC P, whose concentrated share disposals have weighed heavily on market sentiment.</p><p>Notably, the Life Sciences Tools & Services sector posted broad gains on the day, with Thermo Fisher Scientific up 2.71%, Waters up 2.38%, and Agilent up 2.09%, highlighting that Tempus AI's weakness is stock-specific rather than sector-driven. The divergence underscores the outsized selling pressure at the individual stock level.</p><p>The stock had previously rallied significantly following FDA approval of its xT CDx next-generation sequencing platform, which made the company the first laboratory to hold FDA companion diagnostic approvals for both tumor-only and tumor-normal genomic profiling. The current decline is viewed as an extension of profit-taking combined with sustained institutional selling pressure following that run-up.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Tempus AI Falls 5.47% in Regular Trading, Major Shareholder Continued Selling Pressures Market Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Tempus AI Falls 5.47% in Regular Trading, Major Shareholder Continued Selling Pressures Market Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-10 00:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 10, Tempus AI fell 5.47% in regular trading, trading at $45.965/share, with trading volume of $147 million. The decline comes amid persistent selling by major shareholder LEFKOFSKY ERIC P, whose concentrated share disposals have weighed heavily on market sentiment.</p><p>Notably, the Life Sciences Tools & Services sector posted broad gains on the day, with Thermo Fisher Scientific up 2.71%, Waters up 2.38%, and Agilent up 2.09%, highlighting that Tempus AI's weakness is stock-specific rather than sector-driven. The divergence underscores the outsized selling pressure at the individual stock level.</p><p>The stock had previously rallied significantly following FDA approval of its xT CDx next-generation sequencing platform, which made the company the first laboratory to hold FDA companion diagnostic approvals for both tumor-only and tumor-normal genomic profiling. The current decline is viewed as an extension of profit-taking combined with sustained institutional selling pressure following that run-up.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TEM","symbol_name":"Tempus AI","start_time":0,"source_url":"","article_id":"1125284512","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1125284512","pubTimestamp":1781021030,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 10, Tempus AI fell 5.47% in regular trading, trading at $45.965/share, with trading volume of $147 million. The decline comes amid persistent selling by major shareholder LEFKOFSKY ERIC P,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TEM":"Tempus AI"},"translate_title":"动向提示|腾邦AI常规交易跌5.47%大股东持续抛压市场情绪","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEM":1},"content_text":"On June 10, Tempus AI fell 5.47% in regular trading, trading at $45.965/share, with trading volume of $147 million. The decline comes amid persistent selling by major shareholder LEFKOFSKY ERIC P, whose concentrated share disposals have weighed heavily on market sentiment.Notably, the Life Sciences Tools & Services sector posted broad gains on the day, with Thermo Fisher Scientific up 2.71%, Waters up 2.38%, and Agilent up 2.09%, highlighting that Tempus AI's weakness is stock-specific rather than sector-driven. The divergence underscores the outsized selling pressure at the individual stock level.The stock had previously rallied significantly following FDA approval of its xT CDx next-generation sequencing platform, which made the company the first laboratory to hold FDA companion diagnostic approvals for both tumor-only and tumor-normal genomic profiling. The current decline is viewed as an extension of profit-taking combined with sustained institutional selling pressure following that run-up.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1125284512","isCrawlerRequest":true}